(GRADUATE) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer’s Disease

The PI of this project is: Sanjay Asthana, MD

This project is funded by: Pharmaceutical

The term of this project is: October 2018 to October 2021

The number of subjects scanned during this project is: 10

We are conducting a research study on an investigational new drug called gantenerumab vs. a placebo on participants and their memory problems. Researchers also want to find out if gantenerumab is safe. This study may provide further understanding of Alzheimer’s disease and potential benefits of gantenerumab for these people. Before any dose increase, participants will have an MRI brain scan to check that the dose can be increased safely.